Cormorant Asset Management, LP and Bihua Chen filed a Schedule 13G with the SEC on November 16, 2026, disclosing a 9.99% beneficial ownership stake in Cue Biopharma, Inc. (NASDAQ:CUE) as of the event date of September 30, 2026.
Key Highlights
- Beneficial ownership: Both Cormorant Asset Management, LP and Bihua Chen each report aggregate beneficial ownership of 791,377 shares of Cue Biopharma common stock.
- Ownership percentage: The 791,377 shares represent 9.99% of the class, calculated against 7,757,099 shares outstanding as of September 21, 2026.
- Direct share holdings: The reporting persons beneficially own 625,285 shares of common stock directly.
- Pre-funded warrants: The reporting persons also hold warrants exercisable into up to 287,500 shares of common stock, subject to a 9.99% beneficial ownership cap that limits exercise if the threshold would be exceeded.
- Voting and dispositive power: Both reporting persons report zero sole voting or dispositive power, with 791,377 shares held under shared voting and shared dispositive power.
- Dividend rights: According to the filing, Cormorant Global Healthcare Master Fund, LP has the right to receive or direct dividends or sale proceeds attributable to more than 5% of the reported shares.
Cormorant and Bihua Chen Disclose Stake via Pre-Funded Warrants in Cue Biopharma
According to the Schedule 13G filed on November 16, 2026, Cormorant Asset Management, LP, a Delaware limited partnership serving as investment adviser to certain funds referred to in the filing as the "Cormorant Funds," and Bihua Chen, a United States citizen identified as the managing member, jointly reported a 9.99% beneficial ownership position in Cue Biopharma, Inc. The event triggering the filing is dated September 30, 2026, and the issuer's principal offices are listed at 100 Chestnut Street, Suite 300, Somerville, MA 02143.
The filing states that the reported holdings "reflect shares of common stock of the Issuer issuable upon the exercise of pre-funded warrants," with the warrants subject to a cap preventing exercise if doing so would cause the holder and its affiliates to exceed 9.99% of the issuer's then-outstanding common stock. The reporting persons hold 625,285 shares of common stock outright and warrants to acquire up to 287,500 additional shares. The filing notes that "if not for such 9.99% limitation, the Reporting Persons would beneficially own in excess of 9.99% of the Issuer's Common Stock."
The percentage calculation is based on issuer-confirmed share count of 7,757,099 shares outstanding as of September 21, 2026. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The reporting persons are classified as types IA and PN (Cormorant Asset Management, LP) and HC and IN (Bihua Chen).
What Was Disclosed
Cormorant Asset Management, LP and Bihua Chen filed a Schedule 13G disclosing combined beneficial ownership of 791,377 shares, equal to 9.99% of Cue Biopharma's common stock, including shares issuable under pre-funded warrants subject to an ownership cap.




Please wait processing your request...